{"id":1861,"date":"2026-02-04T15:36:27","date_gmt":"2026-02-04T14:36:27","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/calisma-hedefine-ulasildi-rosella-calismasinin-sonuclari\/"},"modified":"2026-02-20T11:28:50","modified_gmt":"2026-02-20T10:28:50","slug":"calisma-hedefine-ulasildi-rosella-calismasinin-sonuclari","status":"publish","type":"post","link":"https:\/\/studienportal-eierstockkrebs.de\/tr\/calisma-hedefine-ulasildi-rosella-calismasinin-sonuclari\/","title":{"rendered":"\u00c7al\u0131\u015fma hedefine ula\u015f\u0131ld\u0131! &#8211; ROSELLA \u00e7al\u0131\u015fmas\u0131n\u0131n sonu\u00e7lar\u0131"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"1861\" class=\"elementor elementor-1861 elementor-1849\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e438c86 e-flex e-con-boxed e-con e-parent\" data-id=\"e438c86\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2cf51b7 elementor-widget elementor-widget-heading\" data-id=\"2cf51b7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\"><strong>Platine diren\u00e7li yumurtal\u0131k kanserinin tedavisine ili\u015fkin yeni bulgular<\/strong> - ROSELLA \u00e7al\u0131\u015fmas\u0131n\u0131n sonu\u00e7lar\u0131<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-070f551 elementor-widget elementor-widget-text-editor\" data-id=\"070f551\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Ocak ay\u0131n\u0131n sonunda, ila\u00e7 \u015firketi Corcept Therapeutics, ROSELLA \u00e7al\u0131\u015fmas\u0131n\u0131n olumlu sonu\u00e7lar\u0131na ili\u015fkin bir bas\u0131n a\u00e7\u0131klamas\u0131 yay\u0131nlad\u0131!<\/p><p data-start=\"310\" data-end=\"622\">Bu \u00e7al\u0131\u015fmada <strong data-start=\"476\" data-end=\"492\">Relacorilant<\/strong> ilac\u0131 ile <strong data-start=\"515\" data-end=\"533\">nab-paklitaksel<\/strong> kemoterapisinin kombinasyonunun <strong data-start=\"569\" data-end=\"605\">platine diren\u00e7li yumurtal\u0131k kanserli<\/strong> hastalar\u0131n sa\u011fkal\u0131m\u0131n\u0131 iyile\u015ftirip iyile\u015ftiremeyece\u011fi ara\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r.<\/p><h3 data-start=\"624\" data-end=\"660\"><strong data-start=\"628\" data-end=\"660\">\u00c7al\u0131\u015fma ne hakk\u0131ndayd\u0131?<\/strong><\/h3><p data-start=\"661\" data-end=\"924\">Platine diren\u00e7li yumurtal\u0131k kanseri, t\u00fcm\u00f6r\u00fcn platin bazl\u0131 kemoterapiye ra\u011fmen b\u00fcy\u00fcmeye devam etti\u011fi ve standart tedavilere yaln\u0131zca s\u0131n\u0131rl\u0131 \u00f6l\u00e7\u00fcde yan\u0131t verdi\u011fi anlam\u0131na gelir. Bu t\u00fcr hastalar genellikle k\u00f6t\u00fc bir prognoza ve yaln\u0131zca s\u0131n\u0131rl\u0131 tedavi se\u00e7eneklerine sahiptir. <\/p><p data-start=\"926\" data-end=\"1005\">ROSELLA \u00e7al\u0131\u015fmas\u0131nda, d\u00fcnya \u00e7ap\u0131nda <strong data-start=\"955\" data-end=\"975\">381 hasta<\/strong> rastgele iki gruba ayr\u0131lm\u0131\u015ft\u0131r:<\/p><ul data-start=\"1006\" data-end=\"1130\"><li data-start=\"1006\" data-end=\"1079\"><p data-start=\"1008\" data-end=\"1079\">Bir grup <strong data-start=\"1028\" data-end=\"1053\">tek ba\u015f\u0131na nab-paklitaksel<\/strong> (standart kemoterapi) alm\u0131\u015ft\u0131r,<\/p><\/li><li data-start=\"1080\" data-end=\"1130\"><p data-start=\"1082\" data-end=\"1130\">di\u011fer <strong data-start=\"1093\" data-end=\"1129\">nab-Paklitaksel art\u0131 Relakorilant<\/strong>.<\/p><\/li><\/ul><h3 data-start=\"1132\" data-end=\"1167\"><strong data-start=\"1136\" data-end=\"1167\">\u00c7al\u0131\u015fma ne g\u00f6sterdi?<\/strong><\/h3><p data-start=\"1169\" data-end=\"1448\">\ud83d\udccc <strong data-start=\"1172\" data-end=\"1204\">1. Daha d\u00fc\u015f\u00fck \u00f6l\u00fcm riski<\/strong><br data-start=\"1204\" data-end=\"1207\">Kemoterapiye ek olarak Relacorilant alan hastalar\u0131n <strong data-start=\"1289\" data-end=\"1329\">\u00f6l\u00fcm riski<\/strong>, tek ba\u015f\u0131na kemoterapi alanlara g\u00f6re <strong data-start=\"1289\" data-end=\"1329\">%35 daha d\u00fc\u015f\u00fckt\u00fc<\/strong>. Bu, yeni kombinasyonun <strong data-start=\"1419\" data-end=\"1438\">genel sa\u011fkal\u0131m\u0131<\/strong> \u00f6nemli \u00f6l\u00e7\u00fcde uzatt\u0131\u011f\u0131 anlam\u0131na gelmektedir. <\/p><p data-start=\"1450\" data-end=\"1642\">\ud83d\udccc <strong data-start=\"1453\" data-end=\"1482\">2. Daha uzun hayatta kalma s\u00fcresi<\/strong><br data-start=\"1482\" data-end=\"1485\">Ortalama olarak, Relacorilant hastalar\u0131, tek ba\u015f\u0131na kemoterapi ile 11,9 aya k\u0131yasla 16,0 ay ya\u015fad\u0131 &#8211; yani yakla\u015f\u0131k <strong data-start=\"1622\" data-end=\"1641\">4 ay daha uzun<\/strong>.<\/p><p data-start=\"1644\" data-end=\"1865\">\ud83d\udccc <strong data-start=\"1647\" data-end=\"1691\">3. Daha iyi progresyonsuz sa\u011fkal\u0131m<\/strong><br data-start=\"1691\" data-end=\"1694\">Kombinasyonun hastal\u0131\u011f\u0131n ilerlemesine kadar ge\u00e7en s\u00fcreyi, yani t\u00fcm\u00f6rlerin daha fazla b\u00fcy\u00fcmedi\u011fi s\u00fcreyi de iyile\u015ftirdi\u011fi daha \u00f6nce g\u00f6sterilmi\u015ftir.<\/p><p data-start=\"1867\" data-end=\"2163\">\ud83d\udccc <strong data-start=\"1870\" data-end=\"1892\">4. \u0130yi tolere<\/strong> edildi<br data-start=\"1892\" data-end=\"1895\">\u00d6nemli: Kombinasyon iyi tolere edildi ve ciddi <strong>yan etkiler<\/strong> tek ba\u015f\u0131na kemoterapiye g\u00f6re <strong data-start=\"1979\" data-end=\"2001\">daha s\u0131k g\u00f6r\u00fclmedi<\/strong>. Bu, Relacorilant&#8217;\u0131n hastalar i\u00e7in g\u00fcvenli\u011fi belirgin \u015fekilde k\u00f6t\u00fcle\u015ftirmeden faydalar\u0131n\u0131 sa\u011flad\u0131\u011f\u0131 anlam\u0131na gelir. <\/p><p data-start=\"2165\" data-end=\"2437\">\ud83d\udccc <strong data-start=\"2168\" data-end=\"2204\">5. Biyobelirte\u00e7 k\u0131s\u0131tlamas\u0131 yok<\/strong><br data-start=\"2204\" data-end=\"2207\">Di\u011fer baz\u0131 tedavilerin aksine, bu \u00e7al\u0131\u015fmada hastalar\u0131 belirli bir t\u00fcm\u00f6r biyobelirte\u00e7ine g\u00f6re se\u00e7mek gerekli de\u011fildi &#8211; tedavinin faydalar\u0131 belirli t\u00fcm\u00f6r <strong>\u00f6zelliklerinden ba\u011f\u0131ms\u0131zd\u0131<\/strong>.<\/p><h3 data-start=\"2439\" data-end=\"2496\"><strong data-start=\"2443\" data-end=\"2496\">Bu Almanya&#8217;daki hastalar i\u00e7in ne anlama geliyor?<\/strong><\/h3><p data-start=\"2498\" data-end=\"2784\"><strong data-start=\"2501\" data-end=\"2551\">Ufukta umut verici yeni tedavi se\u00e7ene\u011fi<\/strong><br data-start=\"2551\" data-end=\"2554\">Sonu\u00e7lar \u00f6zellikle \u00f6nemlidir \u00e7\u00fcnk\u00fc ilk kez ek bir maddenin sadece progresyonu geciktirmekle kalmay\u0131p ayn\u0131 zamanda genel sa\u011fkal\u0131m\u0131 da uzatt\u0131\u011f\u0131n\u0131 g\u00f6stermektedir &#8211; ek g\u00fcvenlik sorunlar\u0131 olmadan.<\/p><p data-start=\"2786\" data-end=\"3192\">Ruhsat <strong data-start=\"2789\" data-end=\"2825\">ba\u015fvurular\u0131 \u015fu anda incelenmektedir<\/strong><br data-start=\"2825\" data-end=\"2828\">&#8211; ABD&#8217;de, G\u0131da ve \u0130la\u00e7 Dairesi (FDA) \u015fu anda Corcept&#8217;in platine diren\u00e7li yumurtal\u0131k kanseri i\u00e7in Relacorilant onay ba\u015fvurusunu incelemektedir; 11 Temmuz 2026&#8217;ya kadar bir sonu\u00e7 beklenmektedir.<br data-start=\"3043\" data-end=\"3046\">&#8211; Avrupa&#8217;da &#8211; Almanya dahil &#8211; ruhsat ba\u015fvurusu da \u015fu anda Avrupa \u0130la\u00e7 Ajans\u0131 (EMA) taraf\u0131ndan de\u011ferlendirilmektedir.<\/p><p data-start=\"3194\" data-end=\"3477\">\u27a1\ufe0f <strong data-start=\"3197\" data-end=\"3257\">Onaylanana kadar Almanya&#8217;da standart olarak kalmayacak<\/strong><br data-start=\"3257\" data-end=\"3260\">Relacorilant resmi olarak onaylanana kadar, bu kombinasyon <strong data-start=\"3335\" data-end=\"3390\">hen\u00fcz<\/strong> Almanya&#8217;daki <strong data-start=\"3335\" data-end=\"3390\">d\u00fczenli tedavi k\u0131lavuzlar\u0131n\u0131n bir par\u00e7as\u0131 de\u011fildir<\/strong>. Ancak mevcut veriler bu y\u00f6nde at\u0131lm\u0131\u015f \u00f6nemli bir ad\u0131md\u0131r. <\/p><p><span style=\"color: #29b8ce;\"><strong>Kaynak:<\/strong> <\/span><a href=\"https:\/\/ir.corcept.com\/news-releases\/news-release-details\/overall-survival-primary-endpoint-met-corcepts-pivotal-phase-3\/\" target=\"_blank\" rel=\"noopener\">Corcept&#8217;ten bas\u0131n a\u00e7\u0131klamas\u0131<\/a> (makale \u0130ngilizcedir)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Platine diren\u00e7li yumurtal\u0131k kanserinin tedavisine ili\u015fkin yeni bulgular &#8211; ROSELLA \u00e7al\u0131\u015fmas\u0131n\u0131n sonu\u00e7lar\u0131 Ocak ay\u0131n\u0131n sonunda, ila\u00e7 \u015firketi Corcept Therapeutics, ROSELLA \u00e7al\u0131\u015fmas\u0131n\u0131n olumlu sonu\u00e7lar\u0131na ili\u015fkin bir bas\u0131n a\u00e7\u0131klamas\u0131 yay\u0131nlad\u0131! Bu \u00e7al\u0131\u015fmada Relacorilant ilac\u0131 ile nab-paklitaksel kemoterapisinin kombinasyonunun platine diren\u00e7li yumurtal\u0131k kanserli hastalar\u0131n sa\u011fkal\u0131m\u0131n\u0131 iyile\u015ftirip iyile\u015ftiremeyece\u011fi ara\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r. \u00c7al\u0131\u015fma ne hakk\u0131ndayd\u0131? Platine diren\u00e7li yumurtal\u0131k kanseri, t\u00fcm\u00f6r\u00fcn platin bazl\u0131 [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":2392,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49],"tags":[],"class_list":["post-1861","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-haberler"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/comments?post=1861"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1861\/revisions"}],"predecessor-version":[{"id":1865,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1861\/revisions\/1865"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/media\/2392"}],"wp:attachment":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/media?parent=1861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/categories?post=1861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/tags?post=1861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}